What it sells
Curing cancer. Starting with dogs.
Business model breakdown
Buyer: who owns the budget?
Owners of dogs with cancer (initially mast cell cancer, Australia) and referring veterinary oncologists.
Trigger: what makes them buy now?
Dog diagnosed with cancer where surgery, chemotherapy or immunotherapy have not worked.
Workflow: what inputs become what output?
Review and intake, vet confirms diagnosis and ships tumour sample and matched blood to genomics lab, mutations analysed and personalised mRNA vaccine designed (~4 weeks), vet oncologist administers.
Economics: what it saves and how it charges
Pre-commercial; no price stated. Claims ~75% tumour reduction in first documented case and under 20 minutes of vet time for design review.
Distribution: how it reaches customers
Vet referral form and owner interest registration; recruiting for an Australian trial.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-12 | — | $4M | — | news.google.com |
| — | Y Combinator Summer 2026 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-17.